Date: May 28, 2019 Source: Business Wire (
click here to go to the source)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kytopen, a technology startup accelerating the discovery and manufacturing of gene-modified cell therapies, today announced it has raised $3.6 million in seed financing from The Engine, Horizons Ventures and angel investors.
"In the short time since The Engine's first investment, Kytopen has made significant progress in developing a platform that is demonstrably faster, more efficient and more scalable than traditional methods"
Founded by two MIT engineers, Kytopen is developing FlowfectTM, the company's proprietary non-viral cell engineering platform which can process a therapeutic payload of cells in seconds.
"Gene-modified cell therapies have the potential to address incurable diseases and fundamentally change the way medicine is practiced, but currently suffer from major challenges in efficiency, reproducibility and manufacturing cost," said Paulo Garcia, Kytopen's CEO and co-founder. "Kytopen's automated cell engineering platform aims to tackle these huge bottlenecks. The new investment will power the ongoing development of Flowfect™ which will enable new discoveries in biology and cost-effective cell therapy manufacturing."
The Engine, the venture capital firm launched by MIT to invest in early-stage Tough Tech companies, had invested in Kytopen's pre-seed round in 2017.
"In the short time since The Engine's first investment, Kytopen has made significant progress in developing a platform that is demonstrably faster, more efficient and more scalable than traditional methods," said Katie Rae, CEO and managing partner of The Engine. "We're excited to invest again in Kytopen and help accelerate their path to market as they aim to transform the cell and gene therapy industry by dramatically improving the efficiency of cell engineering."
